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a b s t r a c t
Data on preparation and characterization of chitosan-based
nanoparticles (NP) carrying small interfering RNA (siRNA) for
non-invasive gene therapy is presented. Polyelectrolyte complex-
ation method was carried out in diluted concentrations to obtain
relatively small (less than 200 nm) NP. To provide substantial dose
of siRNA within tolerable volume of intranasal administration the
NP were subjected to enrichment process. Offered here NP fabri-
cation does two steps process comprise provisional and enriched
preparations? The differences between these preparations were
analyzed with hydrodynamic size distribution and zeta potential
measurements. The effect of siRNA lipophilicity on NP physical
instability was also tested. Biological evaluation of nanoparticles is
described in our published article [1].
© 2020 The Author(s). Published by Elsevier Inc. This is an open
access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).
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1. Data
Here, we present data obtained on enrichment and characterization of chitosan-based NP carrying
siRNA of different lipophilicity [1].
Fig. 1 presents the ﬂow chart of two-steps fabrication of NP comprising polyelectrolyte
complexation of diluted ingredients including small interfering RNA (siRNA), Mn-Dipyridoxal
diphosphate (Mn-DPDP) as crosslinker and chitosan (CS) resulted in formation of provisional nano-
particles (P) and enriched preparation (E).
Polyelectrolyte complexation reaction was performed with siRNA ranged from 10.9 to 90.7 mM of
ﬁnal concentration. The enriched nanoparticles E were fabricated from single P preparation obtained at
the lowest concentration of siRNA (10.9 mM) by up to 12-fold enrichment processing that brought
siRNA concentration to 130.5 mM.
Carrying out reaction of polyelectrolyte complexation by increasing concentration of siRNA has
caused exponential growth of NP size. Experimental results indicate (Fig. 2) that application of siRNA
solutions at concentrations above 32 mM limits the ability to obtain an acceptable NP size (below 200
nm). Thus, reliable fabrication of chitosan-based nanoparticles is possible only in diluted concentra-
tions of all components that raise volume of preparation. However, the tolerable volume is very limited
for intranasal administration. To lower volume of NP preparation and to provide necessary dose of
siRNA for intranasal administration P preparation was subjected to enrichment based on centrifugal
evaporation of water. In the present study, the enrichment protocol has generated 1.5, 3, 6, 9 and
12-fold increased concentrations of siRNA in E preparation.
The number of nanoparticles in given volume is getting low when concentration of ingredients for
complexation reaction increases. Fig. 3 shows changes in NP numbers for both P and E preparations
depending on siRNA content. Increasing the concentration of siRNA in reaction of complexation
negatively affects the NP concentration due to exponentially growing size of NP (Fig. 2). Enrichment
allows obtaining higher concentration of siRNA without substantial changing of the NP size.
Speciﬁcations Table
Subject Nanobiotechnology, gene therapy, non-invasive delivery to the brain
Speciﬁc subject area Fabrication of chitosan nanoparticles with enrichment processing for intranasal delivery of
oligonucleotides to the brain
Type of data Experimental protocols, Tables, Figures
How data were
acquired
Enrichment performed with Eppendorf Vacufuge centrifugal evaporator (Eppendorf, N.Y). The
hydrodynamic size distribution and zeta potential were measured by dynamic light scattering (DLS)
using Malvern Zetasizer Nano ZS90 (Westborough, MA). Index of instability was measured using an
analytical photo centrifuge LUMiSizer (LUM GmbH, Berlin, GER).
Data format Raw and analyzed
Parameters for data
collection
Data obtained by varying siRNA concentration from 10.9 to 130.5 mM, for provisional nanoparticle
preparations and by 1.5, 3, 6, 9 and 12-fold enrichment for enriched preparation. Concentration of
chitosan was varied reciprocally to obtain molecular ratio Chitosan/siRNA of 0.31.
Description of data
collection
Data were collected by measurement of physical stability depending on chemical structure and
concentration of ingredients employed for fabrication of nanoparticles.
Data source location Department of Neurology, University of South Florida, Tampa, Florida, USA
Data accessibility With article and Supplemental Data
Related research article V. Sava, O. Fihurka, A. Khvorova, J. Sanchez-Ramos. Enriched Chitosan Nanoparticles Loaded with
siRNA are Effective in Lowering Huntington's Disease Gene Expression Following Intranasal
Administration. Nanomedicine: Nanotechnology, Biology, and Medicine 24, (2020) 102119
Value of the Data
 The paper relates to the research of nanoparticle-based biomaterials for biomedical applications.
 This dataset presents a protocol for synthesis and characterization of a new bio-nanoparticles, which could be used by
researchers in the same area.
 The data include a preliminary assessment of novel nanoparticles for silencing of HTT gene in brain
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Enrichment helps to increase siRNA dose delivered via nanoparticle intranasal administration.
However, enrichment of nanoparticles may introduce some instability to preparation. Performed
measurements did not discover any noticeable negative effect of enrichment on stability of nano-
particles. In case of using more hydrophilic siRNA (with no conjugated cholesterol), the enriched
nanoparticles become evenmore stable as comparedwith provisional preparation. This is an important
value of the proposed method of NP fabrication.
Fig. 4 is depicted effect of enrichment on physical instability of NP in association with siRNA
lipophilicity. The instability index [2] expressed in arbitrary units (AU) ranged from 0 (most stable) to 1
(most unstable).
2. Experimental design, materials, and methods
2.1. Polyelectrolyte complexation
For polyelectrolyte complexation the equal volumes of chitosan and siRNA solutions were blended
undervigorous stirringat roomtemperature. ConcentrationsofCSvaried from6 to60mM.Concentrations
of siRNAvaried from21.8 to 181.4mMandwere premixedwithMn-DPDP. Concentration ofMn-DPDPwas
from0 to 1.5mMdependingondesired crosslinkingdensityas previously described [3,4].Molecular ratio
(MR) between concentrations of chitosan and siRNA was kept optimal in all preparations. The value of
optimal MR was established during preliminary investigation of most appropriate conditions for
Fig. 1. Flow chart of NP fabrication. Enrichment rate (ER) was calculated as quotient of P and E volumes.
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Fig. 2. Changes of nanoparticle size for P (circles) and E (squares) preparations in relation with siRNA concentration. E nanoparticles
were obtained from the lowest size of P preparation by enrichment procedure. Concentration of CS was as required to maintain
molecular ratio of 0.31.
Fig. 3. Changes of nanoparticle concentration in P (circles) and E (squares) preparations in relation with siRNA concentration.
Fig. 4. Physical instability of chitosan nanoparticles loaded with cholesterol contained siRNA (siRNA-Chol) and cholesterol-free
(siRNA-no Chol). Closed and open bars represent P and E preparation, respectively.
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polyelectrolyte complexation leading to formation NP below 200 nm and with positive zeta-potential
between 30 and 55 mV. It was established MR¼ 0.31 for present experiments.
2.2. Enrichment of nanoparticles for in vivo administration
The enrichment of NP was carried out with Eppendorf Vacufuge centrifugal evaporator (Eppendorf,
N.Y) partially eliminating solvent from nanoparticle preparation. Evaporation temperature was set to
40 C and centrifugation time was in range 2e4 hours at 1400 rpm. NP size of obtained E preparation
was ranged from 90 to 200 nm with zeta potential between þ42 and þ 55 mV.
2.3. Materials
Chitosan (CS) of lowmolecular weight (60,000e120,000 Dawith 85% deacetylation) was purchased
from Sigma-Aldrich, MO. CS was dissolved in 0.5% acetic acid to obtain 60 mM stock solution that was
passed through a syringe ﬁlter (pore size 0.2 mm, Millipore, USA) before dilution to working concen-
trations in ultrapure RNase free water.
Two different double stranded RNA oligonucleotides synthesized at the University of Massachusetts
(UMASS) RNA Institute [5] were used for nanoparticle preparation. There were two types of siRNA
designated for silencing HTT gene. One of them (cy3 HTT 10150- P2VP-Chol) contained cholesterol
conjugated at the 3’ end of antisense strain. Another one (cy3 HTT 10150-P2VP) has 3'-end free. Stock
concentration of siRNA was 196 mM prepared on RNase-free water.
Mn-DPDP was purchased from U.S. Pharmacopeial Convention (Rockville, MD). It was dissolved in
ultrapure RNase free water to form 1.5. mM stock solution passed through a syringe ﬁlter (pore size 0.2
mm, Millipore, USA) before use.
3. Methods
3.1. Nanoparticle size and zeta potential
The hydrodynamic size distribution and zeta potential in NP preparations were determined at 25 C
by dynamic light scattering measurements with Malvern Zetasizer Nano ZS90 (Westborough, MA).
3.2. Physical stability of NP
Physical stability of the nanoparticles was determined on an analytical photo centrifuge LUMiSizer
(LUM GmbH, Berlin, GER). Measurements were performed by using quantity of transmitted near
infrared light (870 nm) as a function of time and position of sedimentation boundary in centrifuge
cuvette. Testing parameters were as follows: cuvette volume e 200 mL; rotation speed e 4000 rpm;
time interval e 30 s; number of measurements - 255; temperature - 25 C. Special software SEP view
5.1 was used for the analysis.
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